Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 15, Issue 1, 1997, Pages 28-34

  Fischl, Margaret A ^a   Richman, Douglas D ^b   Flexner, Charles ^c   Para, Michael F ^d   Haubrich, Richard ^b   Karim, Aziz ^e   Yeramian, Patrick ^f   Holden Wiltse, Jeanne ^f   Meehan, Patricia M ^f  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e PFIZER INC   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antiretroviral therapy; HIV 1 protease inhibitor

Indexed keywords

PROTEINASE INHIBITOR; TELINAVIR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DYSPNEA; FEMALE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0030769322     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199705010-00005     Document Type: Article

References (21)

1. Getman DD, DeCrescenzo GA, Heintz RM, et al. Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R-hydroxyethyl) urea isostere. J Med Chem 1993;36:288-91.
2. Lam PYS, Jadhav PK, Eyemann CJ, et al. Rational design of potent, bioavailable, non-peptide cyclic ureas as HIV protease inhibitors. Science 1994;263:380-2.
3. Pillay D, Bryant M, Getman D, Richman DD, HIV-1 protease inhibitors: their development, mechanism of action and clinical potential. Rev Med Virol 1995;5:23-33.
4. Roberts NA, Martin JA, Kinchington D, et al. Rational design of peptide-based HIV proteinase inhibitors. Science 1990;248:358-61.
5. Vacca JP, Dorsey BD, Schleif WA, et al. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci USA 1994;91:4096-100.
6. Wlodawer A, Erickson JW. Structure-based inhibitors of HIV-1 protease. Annu Rev Biochem 1993;36:543-85.
7. Kitchen VS, Skinner C, Ariyoshi K, et al. Safety and activity of saquinavir in HIV infection. Lancet 1995;345:952-5.
8. Markowitz M, Saag M, Powderly WG, et al. A preliminary study or ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-9.
9. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995;333:1528-33.
10. Steigbigel RT, Berry P, Mellors J, et al. Efficacy and safety of the HIV protease inhibitor indinavir sulfate (MK 639) at escalating dose (Abstract 146). In: Program and abstracts of the Third Conference on Retroviruses and Opportunistic Infections. Washington, DC, 1996:80.
11. Condra JH, Holder DJ, Schleif WA, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996;70:8270-6.
12. Eastman PS, Kelso R, Boyer E, et al. Loss of suppression of viral replication by ritonavir (ABT-538) is quantitatively associated with the acquisition of genotypic mutations at codon 82 of the HIV-1 protease gene (Abstract 201). In: Program and abstracts of the Third Conference on Retroviruses and Opportunistic Infections. Washington, DC, 1996:90.
13. Bryant M, Getman D, Smidt M, et al. SC-52151, a novel inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1995;39:2229-34.
14. Karim A, Gokhale R, Cole M, et al. HIV protease inhibitor SC-52151: a novel method of optimizing bioavailability profile via a microemulsion drug delivery system. Pharm Res 1994;11:5368.
15. Ho DD, Neumann AU, Perelson AS, Chen W Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
16. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995:373:117-22.
17. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span and viral generation time. Science 1996;271:1582-6.
18. Kageyama S, Anderson BD, Hoesterey B, et al. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of protein. Antimicrob Agents Chemother 1994;38:1107-11.
19. 1 acid glycoprotein. J Infect Dis 1995;171:559-65.
20. Sommadossi J-P, Schinazi RF, McMillan A, Xie M-Y, Bryant M. A human serum glycoprotein profoundly affects antiviral activity of the protease inhibitor SC-52151 by decreasing its cellular uptake (Abstract LB4). In: Program and abstracts for the Second National Conference of Human Retroviruses and Related Infections. Washington, DC, 1995:167.
21. Flexner C, Richman DD, Bryant M, et al. Effect of protein binding on the pharmacodynamics of an HIV protease inhibitor [Abstract]. Antiviral Res 1995;26:A282.